ibi315
mAbexperimentalMulti-specific
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Nov 26, 2019 (NCT04162327)
Timeline
2010s
- Jan 1, 2019
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Programmed cell death protein 1INHIBITOR
PDCD1 inhibitor
ERBB2 inhibitor
Chemistry & pharmacology
- Multi-specific
- Yes
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05608785 | Phase 1/Phase 2 (Phase 2) | Jan 1, 2023 | Henan Medical University |
| NCT04162327 | Phase 1 | Nov 26, 2019 | Innovent Biologics (Suzhou) Co. Ltd. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Henan Medical University | Academic/Hospital | 1 | 1 | 1 | 2023 |
| Innovent Biologics (Suzhou) Co. Ltd. | For profit | 1 | 1 | 1 | 2019 |
2 organizations
Page 1 / 1